Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Acq. announced
Inv. presentation
Quarterly results

Furiex Pharmaceuticals, Inc. (FURX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/03/2014 8-K Form 8-K - Current report
07/01/2014 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger"
05/28/2014 8-K Submission of Matters to a Vote of Security Holders
05/07/2014 8-K Quarterly results
Docs: "Furiex Pharmaceuticals Reports First Quarter 2014 Financial Results",
"Presentation on May 6, 2014, regarding eluxadoline"
04/28/2014 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty"
03/11/2014 8-K Quarterly results
Docs: "Furiex Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results"
02/04/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Furiex Pharmaceuticals Announces Positive Top-Line Results of Two Pivotal Phase III Clinical Trials of Eluxadoline in Patients with IBS-d"
11/05/2013 8-K Quarterly results
Docs: "Furiex Reports Third Quarter 2013 Financial Results"
11/01/2013 8-K Form 8-K - Current report
10/04/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amended and Restated Loan and Security Agreement dated September 30, 2013, by and among MidCap Funding III, LLC, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, GenuPro, Inc., and the lenders named therein",
"Second Omnibus Amendment and Reaffirmation Agreement dated September 30, 2013, by and among MidCap Funding III, LLC, LLC, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, and GenuPro, Inc",
"Subordination and Intercreditor Agreement dated September 30, 2013, by and among the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, GenuPro, Inc., and MidCap Funding III, LLC",
"Loan and Security Agreement dated September 30, 2013, by and among the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated, Furiex Pharmaceuticals, Inc., APBI Holdings, LLC, Development Partners, LLC, and GenuPro, Inc",
"Secured Promissory Note dated September 30, 2013, to the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated",
"Pledge Agreement dated September 30, 2013, to Frederic Neville Eshelman, Trustee of the Fredric Neville Eshelman Revocable Trust u/a dated July 13, 1988, as amended and/or restated",
"Furiex Pharmaceuticals Enters into a Loan Agreement for $15 Million and Restructures its Existing Secured Loan"
08/06/2013 8-K Quarterly results
Docs: "Furiex Reports Second Quarter 2013 Financial Results Recent Events:"
05/29/2013 8-K Submission of Matters to a Vote of Security Holders
03/06/2013 8-K Quarterly results
Docs: "Furiex Reports Fourth Quarter and Full Year 2012 Financial Results"
11/01/2012 8-K Quarterly results
Docs: "Furiex Reports Third Quarter 2012 Financial Results"
08/08/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Furiex Pharmaceuticals Amends Current Loan and Security Agreement, Adding an Additional $30.0 Million"
08/02/2012 8-K Quarterly results
Docs: "Furiex Reports Second Quarter 2012 Financial Results"
07/30/2012 8-K Form 8-K - Current report
05/25/2012 8-K Submission of Matters to a Vote of Security Holders
05/15/2012 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "PRESS RELEASE ISSUED MAY 14, 2012.",
"PRESS RELEASE ISSUED MAY 14, 2012."
05/03/2012 8-K Quarterly results
Docs: "Furiex Reports First Quarter 2012 Financial Results"
02/21/2012 8-K Form 8-K - Current report
12/13/2011 8-K Form 8-K - Current report
11/18/2011 8-K Form 8-K - Current report
11/01/2011 8-K Form 8-K - Current report
09/07/2011 8-K Form 8-K - Current report
08/24/2011 8-K Form 8-K - Current report
05/24/2011 8-K Form 8-K - Current report
04/28/2011 8-K Form 8-K - Current report
02/22/2011 8-K Form 8-K - Current report
12/10/2010 8-K Form 8-K - Current report
09/13/2010 8-K Form 8-K - Current report
08/11/2010 8-K Quarterly results
Docs: "Furiex Reports Second Quarter 2010 Financial Results"
06/18/2010 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Separation and Distribution Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Sublease Agreement, by and between Furiex Pharmaceuticals, Inc. and PPD Development, LP",
"Tax Sharing Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Employee Matters Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Transition Services Agreement, by and between Furiex Pharmaceuticals, Inc. and Pharmaceutical Product Development, Inc",
"Master Development Services Agreement, by and between Furiex Pharmaceuticals, Inc. and PPD Development, LP",
"Consulting Agreement, by and between Elk Mountain Consulting, LLC and Furiex Pharmaceuticals, Inc",
"PPD and Furiex Announce Completion of Spin-off"
06/11/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Furiex Pharmaceuticals Confirms Takeda Receives Pricing Approval of NESINA ® in Japan"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy